Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.57 |
| ▸ | AURKA | O14965 | 5/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.57 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.42 |
| ▸ | RPS6KA5 | O75582 | 4/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.42 |
| ▸ | LCK | P06239 | 4/20 | 0.42 |
| ▸ | LYN | P07948 | 4/20 | 0.42 |
| ▸ | RET | P07949 | 4/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.42 |
| ▸ | FLT1 | P17948 | 4/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.42 |
| ▸ | AXL | P30530 | 4/20 | 0.42 |
| ▸ | FLT3 | P36888 | 4/20 | 0.42 |
| ▸ | FRK | P42685 | 4/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.42 |
| ▸ | CLK2 | P49760 | 4/20 | 0.42 |
| ▸ | BLK | P51451 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29503401 | 1.00 | KDR (0.57) | KDRAURKAAURKBEPHB4ROCK2 | |
| SCHEMBL18341971 | 0.79 | KDR (0.40) | KDRAURKAAURKBEPHB4ROCK2 | |
| SCHEMBL4764241 | 0.79 | KDR (0.40) | KDRAURKAAURKBEPHB4ROCK2 | |
| SCHEMBL8284990 | 0.78 | KDR (0.56) | KDRAURKAAURKBEPHB4ROCK2 | |
| SCHEMBL17165793 | 0.78 | KDR (0.77) | KDRAURKAAURKBEPHB4ROCK2 | |
| SCHEMBL17176672 | 0.76 | KDR (0.38) | KDRAURKAAURKBEPHB4ROCK2 | |
| SCHEMBL29503516 | 0.76 | KDR (0.41) | KDRAURKAAURKBEPHB4ROCK2 | |
| SCHEMBL30958677 | 0.76 | KDR (0.38) | KDRAURKAAURKBEPHB4ROCK2 | |
| SCHEMBL379508 | 0.76 | KDR (0.41) | KDRAURKAAURKBEPHB4ROCK2 | |
| SCHEMBL19953915 | 0.76 | KDR (0.53) | KDRAURKAAURKBEPHB4ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833153-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-12-05 | — | — | US | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| EP-3472165-B1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2023-09-06 | — | — | EP | disclosed |
| US-20230107393-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-04-06 | — | — | US | disclosed |
| WO-2023034236-A1 | DEUTERATED INHIBITORS OF RIP KINASES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-03-09 | — | — | WO | disclosed |
| US-11491158-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-11-08 | — | — | US | disclosed |
| US-11472800-B2 | Organic compound and organic electroluminescent device comprising the same | DOOSAN SOLUS CO., LTD. (KR) | 2022-10-18 | — | — | US | disclosed |
| EP-3112351-B1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-03-30 | — | — | EP | disclosed |
| CN-109311894-B | N- (substituted-phenyl) -sulfonamide derivatives as kinase inhibitors | 内尔维阿诺医学科学有限公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2007067781-A2 | 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135387-A1 | Inhibitors of protein kinases | ABBOTT LABORATORIES | 2007-06-14 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1648905-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | Abbott Laboratories (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-1620094-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-01-27 | — | — | US | disclosed |
| WO-2004100947-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107393-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | ATF4, MAP3K1, MAP3K6 | KDR 2509/4885AURKA 902/4885AURKB 1157/4885 |
| US-11491158-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | ATF4, MAP3K1, MAP3K6 | KDR 2509/4885AURKA 902/4885AURKB 1157/4885 |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABL1, MAP4K2, MAP4K5 | KDR 511/4885AURKA 293/4885AURKB 262/4885 |
| US-11833153-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | ATF4, MAP3K1, MAP3K6 | KDR 2509/4885AURKA 902/4885AURKB 1157/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | KDR 494/4885AURKA 207/4885AURKB 171/4885 |
| US-11472800-B2 | Organic compound and organic electroluminescent device comprising the same | VDAC1, OR10J3, VDAC2 | KDR 3365/4885AURKA 1570/4885AURKB 1886/4885 |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | KDR 3973/4885AURKA 2339/4885AURKB 1279/4885 |
| US-20070135387-A1 | Inhibitors of protein kinases | MAP3K20, PACSIN2, MAP4K2 | KDR 2196/4885AURKA 425/4885AURKB 277/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | KDR 494/4885AURKA 207/4885AURKB 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.